WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Thursday, February 9, 2017

Lost in translation: Parkinson's disease research undercut by study design

February 9, 2017  by PLOS ONE.



In a review of animal studies of Parkinson's disease therapies, Yale researchers identified trends that may contribute to the lack of success in human clinical trials. Their finding provides insight to investigators who seek new therapies to slow the progression of the disease.

Many potential therapies for Parkinson's disease that are successful in animal studies fail in human trials, said the researchers at Yale and Albert Einstein College of Medicine. While flaws in study design and reporting in a variety of diseases have been publicized, the research team decided to examine the impact of other study design issues on the development of new therapies.
The research team reviewed more than 500 animal and human studies of Parkinson's disease published over the last 40 years. They compared the design of studies for therapies that targeted symptoms with those intended to slow progression of the disease. In addition to previously described design oversights, such as randomization and blinding, they explored whether the study design in  was aligned with the intended purpose of the therapy in humans.
The researchers found that in studies of therapies to delay the disease, the intervention was given to animals too early—either prior to or soon after disease onset. That stands in stark contrast to how human patients are typically treated.
Additional study shortcomings included a preference for young male animal subjects, a singular time point to assess the outcome, use of measures not validated in clinical settings, and dependence on non-progressive models of Parkinson's disease. These were all factors that impaired the generalizability of results from relatively narrowly defined animal systems to a more complex system, such as humans, the researchers report.
"These data suggest that study designs in animals, particularly mice, are perpetuated based on accepted norms despite little evidence for translation to humans," said first author Caroline Zeiss, professor of comparative medicine at Yale.
"Reproducibility and translation are related but distinct issues—our study focuses predominantly on factors affecting translation. Unless study designs in animals change to reflect the  disease more accurately, proposed measures to improve reproducibility are unlikely to have a significant impact on translation of new therapies to the clinic," Zeiss noted.
Explore further: Breakthrough measures Parkinson's progression in the brain

Journal reference: PLoS ONE

Provided by: Yale University

https://medicalxpress.com/news/2017-02-lost-parkinson-disease-undercut.html

No comments:

Post a Comment